Vanguard Fiduciary Trust’s Biogen BIIB Stock Holding History

Vanguard Fiduciary Trust’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$179M	Buy	829,318 +3,787	+0.5%	+$724K	0.04%	356
2026 Q1	$151M	Buy	+825,531	New	+$152M	0.04%	383

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Fiduciary Trust's BIIB Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Biogen (BIIB) stake by 0.46% in Q2 2026, buying an estimated $724K and bringing the position to 829,318 shares worth $179M. The position accounts for 0.04% of the portfolio, ranked #356.

Vanguard Fiduciary Trust first reported a position in BIIB in Q1 2026 and has held it in 2 quarters since. 1,029 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Vanguard Fiduciary Trust held 829,318 shares of Biogen worth $179M as of Q2 2026.
Vanguard Fiduciary Trust bought 3,787 Biogen shares in Q2 2026, an estimated $724K.
Biogen made up 0.04% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #356 holding.
Vanguard Fiduciary Trust first reported a position in Biogen in Q1 2026 and has held it in 2 quarters since.
1,029 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.